Modulating apoptosis : current applications and prospects for future drug development / H.P. Deigner, R. Kinscherf
Agents modulating apoptosis are of extraordinary promise for the treatment of several states of disease including cancer, AIDS, neurodegenerative and ischemic diseases. In this review a brief summary of cellular pathways relevant to programmed cell death first is given and potential therapeutic targets therein are emphasized. Current efforts in drug development are discussed from a mechanistic, biochemical point of view and pro- and anti-apoptotic strategies are related to the respective diseases. Therapeutic approaches addressed in this paper include the design and activity of novel low molecular weight agents (e.g. caspase inhibitors) as well as gene therapy (e.g. p53, adenovirus as vector in cancer treatment). In final sections, the latest findings in the field of apoptosis are highlighted and future applications are outlined..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
1999 May 1999 |
|---|---|
| Erschienen: |
1999 May |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Current medicinal chemistry - 6(1999), 5, Seite 399-414 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deigner, Hans-Peter, 1958- [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Gesehen am 11.09.2017 |
|---|
| Umfang: |
16 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1563365413 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | 1563365413 | ||
| 003 | DE-627 | ||
| 005 | 20230427122055.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170911s1999 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1563365413 | ||
| 035 | |a (DE-576)493365419 | ||
| 035 | |a (DE-599)BSZ493365419 | ||
| 035 | |a (OCoLC)1340979015 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deigner, Hans-Peter |d 1958- |e verfasserin |0 (DE-588)1012570606 |0 (DE-627)699716705 |0 (DE-576)345618505 |4 aut | |
| 245 | 1 | 0 | |a Modulating apoptosis |b current applications and prospects for future drug development |c H.P. Deigner, R. Kinscherf |
| 264 | 1 | |c 1999 May | |
| 300 | |a 16 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 11.09.2017 | ||
| 520 | |a Agents modulating apoptosis are of extraordinary promise for the treatment of several states of disease including cancer, AIDS, neurodegenerative and ischemic diseases. In this review a brief summary of cellular pathways relevant to programmed cell death first is given and potential therapeutic targets therein are emphasized. Current efforts in drug development are discussed from a mechanistic, biochemical point of view and pro- and anti-apoptotic strategies are related to the respective diseases. Therapeutic approaches addressed in this paper include the design and activity of novel low molecular weight agents (e.g. caspase inhibitors) as well as gene therapy (e.g. p53, adenovirus as vector in cancer treatment). In final sections, the latest findings in the field of apoptosis are highlighted and future applications are outlined. | ||
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Animals | |
| 650 | 4 | |a Antigens, CD95 | |
| 650 | 4 | |a Apoptosis | |
| 650 | 4 | |a Ceramides | |
| 650 | 4 | |a Cysteine Proteinase Inhibitors | |
| 650 | 4 | |a Cytochrome c Group | |
| 650 | 4 | |a Drug Design | |
| 650 | 4 | |a Mitochondria | |
| 650 | 4 | |a NF-kappa B | |
| 650 | 4 | |a Oxidative Stress | |
| 650 | 4 | |a Proto-Oncogene Proteins c-bcl-2 | |
| 650 | 4 | |a Receptors, Tumor Necrosis Factor | |
| 700 | 1 | |a Kinscherf, Ralf |e verfasserin |0 (DE-588)1084823748 |0 (DE-627)848747925 |0 (DE-576)169729516 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current medicinal chemistry |d Hilversum [u.a.] : Bentham Science Publ., 1996 |g 6(1999), 5, Seite 399-414 |h Online-Ressource |w (DE-627)325051623 |w (DE-600)2034240-8 |w (DE-576)273880209 |x 1875-533X |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:1999 |g number:5 |g pages:399-414 |g extent:16 |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/pubmed/10101220 |x Verlag |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a ISIL_DE-16-250 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |d 6 |j 1999 |e 5 |h 399-414 |g 16 |
| 951 | |a AR | ||
| 952 | |d 6 |j 1999 |e 5 |h 399-414 |g 16 | ||
| 980 | |2 2013 |1 01 |x DE-16-250 |b 2979975958 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 11-09-17 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd1999 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_2 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_16 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1559434600 |a Deigner, Hans-Peter | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416535624 |a Institut für Pharmazie und Molekulare Biotechnologie (IPMB) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_1 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s p |0 (DE-627)1526868938 |a Kinscherf, Ralf | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s k |0 (DE-627)1416742018 |a Institut für Anatomie und Zellbiologie | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |a pos_2 | ||